Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2176/nmc.ra.2014-0088 http://scihub22266oqcxt.onion/10.2176/nmc.ra.2014-0088 C4533495!4533495 !25070016     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25070016 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25070016 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Neurol+Med+Chir+(Tokyo) 2014 ; 54 (8 ): 599-605 Nephropedia Template TP {{tp|p=25070016 |t=2014. Adult growth hormone deficiency: current concepts |pdf=|usr=}}{{25070016 }} gab.com Text Adult growth hormone deficiency: current concepts JO: Neurol Med Chir (Tokyo) http://www.kidney.de/pget.php?&tw=1&pmid=25070016 #FOAvip The clinical syndrome of adult growth hormone deficiency (AGHD) was widely recognized in the 1980s. In this review, we first describe the clinical features and diagnosis of AGHD and then state the effects of growth hormone (GH) therapy for these patients. The main characteristics of AGHD are abnormal body composition, dyslipidemia, insulin resistance, and an impaired quality of life (QoL) due to decreased psychological well-being. For diagnosing AGHD, the international consensus guidelines have suggested that an insulin tolerance test (ITT) is the gold standard, but in Japan, the growth hormone releasing peptide-2 (GHRP-2) test is available and is recommended as a convenient and safe GH stimulating test. The cut-off for diagnosing severe AGHD is a peak GH concentration of 9 g/L during the GHRP-2 test. Since 2006, GH therapy has been approved for Japanese patients with severe AGHD. For adults, GH replacement therapy should be initiated at a low dose (3 g/kg body weight/day), followed by individualized dose titration while monitoring patients' clinical status and serum insulin-like growth factor-I (IGF-I) concentrations. A variety of favorable effects of GH replacement have been indicated; however, it has not yet been established fully whether there is a direct effect of GH treatment on reducing mortality. Twit Text FOAVip Adult growth hormone deficiency: current concepts ????Neurol Med Chir (Tokyo) http://www.kidney.de/pget.php?&tw=1&pmid=25070016 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25070016 #FOAvip English Wikipedia <ref>{{Cite pmid|25070016 }}</ref> Adult growth hormone deficiency: current concepts #MMPMID25070016 Fukuda I ; Hizuka N ; Muraoka T ; Ichihara A Neurol Med Chir (Tokyo) 2014[]; 54 (8 ): 599-605 PMID25070016 show ga The clinical syndrome of adult growth hormone deficiency (AGHD) was widely recognized in the 1980s. In this review, we first describe the clinical features and diagnosis of AGHD and then state the effects of growth hormone (GH) therapy for these patients. The main characteristics of AGHD are abnormal body composition, dyslipidemia, insulin resistance, and an impaired quality of life (QoL) due to decreased psychological well-being. For diagnosing AGHD, the international consensus guidelines have suggested that an insulin tolerance test (ITT) is the gold standard, but in Japan, the growth hormone releasing peptide-2 (GHRP-2) test is available and is recommended as a convenient and safe GH stimulating test. The cut-off for diagnosing severe AGHD is a peak GH concentration of 9 g/L during the GHRP-2 test. Since 2006, GH therapy has been approved for Japanese patients with severe AGHD. For adults, GH replacement therapy should be initiated at a low dose (3 g/kg body weight/day), followed by individualized dose titration while monitoring patients' clinical status and serum insulin-like growth factor-I (IGF-I) concentrations. A variety of favorable effects of GH replacement have been indicated; however, it has not yet been established fully whether there is a direct effect of GH treatment on reducing mortality. |Adult [MESH] |Age Factors [MESH] |Body Composition [MESH] |Diagnosis, Differential [MESH] |Dyslipidemias/diagnosis/drug therapy [MESH] |Human Growth Hormone/*deficiency/therapeutic use [MESH] |Humans [MESH] |Insulin Resistance [MESH] |Oligopeptides [MESH]Adult growth hormone deficiency: current concepts (epmc).pdf DeepDyve Pubget Overpricing